The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
REGULATORY
Japan to Add Shingles Vaccines to NIP List from FY2025, Targeting Age 65
A Japanese health ministry panel on December 18 approved a plan to add shingles vaccines to the list of jabs to be covered by the national immunization program (NIP) from FY2025, basically targeting people aged 65. Starting on April 1,…
To read the full story
Related Article
- GSK Applauds Japan’s Plan to Include Shingles Vaccines in NIP
December 19, 2024
- Japan Expected to Include Shingles Vaccines in NIP from FY2025
December 4, 2024
- Pfizer Rolls Out Prevenar 20 in Japan, Pediatric NIP Set to Start October
September 2, 2024
- Prevenar 20 to Join National Immunization for Children from October
August 1, 2024
- Japan Panel Discusses Details of NIP for Shingles Jabs, OKs Inclusion of Prevenar 20
July 19, 2024
- Japan Panel Raises No Objection to Public Coverage of Shingles Vaccines
June 21, 2024
- MHLW Proposes Inclusion of Prevenar 20 in National Immunization for Children
May 24, 2024
REGULATORY
- MHLW Proposes Setting Product Scope for Off-Year Revisions by Category
December 19, 2024
- MHLW to Disclose Company Names under Generic Index Rule Possibly in FY2026
December 19, 2024
- Japan Weighs Tweaking “x0.625” Threshold to Narrow Off-Year Revision Coverage
December 19, 2024
- Japan to Add Shingles Vaccines to NIP List from FY2025, Targeting Age 65
December 19, 2024
- MHLW Orders Label Revisions for SGLT2 Inhibitors, COVID Drugs, and More
December 19, 2024
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…